Piper Sandler cuts Solventum stock price target on model updates By Investing.com

Piper Sandler cut its Solventum price target to $92 from $98 while keeping an Overweight rating, citing model updates for currency and GAAP restructuring charges in 2026. The stock trades at $71.17, down 13% year-to-date, and investors remain focused on potential AI disruption to the Health Information Systems franchise and the pace of buybacks. Recent analyst views are mixed, and the company also disclosed that Chief Accounting Officer Mary Wilcox plans to retire.

Analysis

The cleaner read-through is not the headline price move but the market’s shifting estimate of how much of Solventum’s value sits in a slow-growth, structurally vulnerable franchise versus how much can be recycled into buybacks. At ~10x forward earnings, the market is still treating it like a “show me” compounder; that leaves room for multiple compression if AI fear spreads beyond the core information workflow segment and starts to contaminate expectations for the rest of the portfolio. In that setup, the first-order loser is not just SOLV holders — it is any peer with a similar mix of mature end markets and limited organic growth optionality.

The second-order issue is capital allocation credibility. If management steps up repurchases into weakness, that can create a near-term floor, but only if investors believe cash generation is durable and not being borrowed from the future via underinvestment or restructuring noise. If buybacks remain modest while the stock keeps drifting lower, the market will likely infer that management sees more reinvestment need than it is admitting, which tends to hurt valuation more than the absolute pace of EPS beats.

The contrarian angle is that the selloff may already be discounting a much worse AI disruption path than is likely to show up in the numbers over the next 2–3 quarters. Healthcare workflow transitions are usually slow, procurement-led, and contract-bound; that means the real risk is not immediate revenue collapse but a gradual erosion of renewal quality and pricing power. If the company can demonstrate even incremental stability in the exposed segment while continuing repurchases, the stock can re-rate quickly because expectations are low and the base is not expensive.

Key Decisions for Investors

• Short-term: buy SOLV on further weakness only if management signals accelerated repurchases; otherwise avoid catching the knife. Risk/reward improves materially below ~9x forward earnings, where buybacks can offset downside and limit multiple compression.
• Pair trade: long better-executed healthcare services/software names versus short SOLV over the next 1–3 months to express the AI-disruption wedge. The clean thesis is that the market will reward visible growth durability and punish “mature asset” exposure.
• If already long SOLV, hedge with a tactical put spread into the next earnings/date-sensitive update. Use 1–2 quarter tenor to protect against another guidance reset or a renewed AI headline cycle; the downside is likely faster than the upside.
• Watch for evidence of buyback acceleration over the next 30–60 days; if repurchases materially step up, consider a tradeable long on sentiment reversal. That setup offers asymmetric upside because expectations are already low and the stock is not expensive.
• Do not short purely on valuation. The better short is a basket with similar growth skepticism and weaker capital return discipline; SOLV’s shareholder yield can blunt downside if management gets more aggressive.